Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering a...
Lexicon Announces Proposed Public Offering of Common Stock THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the p...
Landmark Bancorp, Inc. Reports Fourth Quarter and Full Year 2025 Results Announces 44.4% Increase in Net Earnings for the Year Ended December 31, 2025 and Fourth Quarter Net Income of $4.7 Million, Diluted Earnings Per Share of $0.77 Declares Quarterly Cash Dividend of $0.21 per Share Manhattan, KS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.77 for the fourth quarter of 2025, compared to $0.81 per share in the third quarter of 2025 and $0.54 per share in the same quarter of the prior year. Net earnings fo...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper understa...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the ...
Landmark Bancorp, Inc. Announces Conference Call to Discuss Fourth Quarter 2025 Earnings Manhattan, KS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (Nasdaq: LARK), the holding company for Landmark National Bank, announced today that it will release earnings for the fourth quarter of 2025 after the market closes on Wednesday, January 28, 2026. The Company will host a conference call to discuss these results on Thursday, January 29, 2026, at 10:00 am (CT). Conference Call Information: Date: Thursday, January 29, 2026Time: 10:00am Central TimeTeleconference Dial-In: (833) 470-...
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET) THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” -White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and id...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco. The live event and replay of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ live...
Landmark Bancorp, Inc. Earns National Recognition as a Top-Performing Small-Cap Bank Landmark Named to Piper Sandler Sm-All Stars Class of 2025 Manhattan, Kansas, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (NASDAQ: LARK), the parent company of Landmark National Bank, has been named to Piper Sandler’s SM-All Stars Class of 2025. Landmark is one of only 24 banks in the U.S. to be named to the annual list of top-performing small-cap institutions. Piper Sandler, a leading investment bank and research firm, annually recognizes institutions based on metrics like growth, profitab...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the . ACSL5 is an enz...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-...
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceutic...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.